|  |  |  |
| --- | --- | --- |
| **Study** | **EMPA-REG**  **Empagliflozin [30, 33]** | **CANVAS (pooled)**  **Canagliflozin [43]** |
| **3P-MACE** | **0.86\***  0.74; 0.99 | **0.86\***  0.75; 0.97 |
| **CV death** | **0.62\***  0.49; 0.77 | 0.87†  0.72; 1.06 |
| **Non-fatal MI** | 0.87  0.70; 1.09 | 0.85  0.69; 1.05 |
| **Non-fatal stroke** | 1.24  0.92; 1.67 | 0.90  0.71; 1.15 |
| **Hospitalized HF** | **0.65\***  0.50; 0.85 | 0.67  0.52; 0.87 |
| **All cause death** | **0.68\***  0.57; 0.82 | 0.87†  0.74, 1.01 |
| **New or worsening nephropathy (composite renal outcome)** | **0.61\***  0.53; 0.70 | 0.60  0.47; 0.77 |
| **New-onset persistent macroalbuminuria** | **0.62\***  0.54; 0.72 | 0.73  0.67; 0.79 |
| **Doubling of serum** **creatinine** | **0.56\***  0.39; 0.79 | NR |
| **Initiation of renal replacement** **therapy** | **0.45\***  0.21; 0.97 | NR |

Additional Table S1 Selected outcomes from SGLT2 inhibitor CVOTs

NR, not reported  
New or worsening nephropathy defined as:  
**EMPA-REG OUTCOME:** progression to macroalbuminuria, doubling of the serum creatinine level, initiation of renal-replacement therapy, or death from renal disease  
**CANVAS trial:** 40% reduction in eGFR, renal-replacement therapy, or renal death   
Doubling of serum creatinine defined as:  
**EMPA-REG OUTCOME trial:** Doubling of serum creatinine level accompanied by eGFR of 45 ml/min/1.73 m2